Saturday 17 October 2026 Export CSBR’s income statement to Excel — free account

Champions Oncology, Inc.

Champions Oncology, Inc.’s revenue for fiscal 2026 (year ended April 2026) was $59.4 million, up 4.36% from fiscal 2025. In the quarter to July 2026, revenue grew 8.84%, EPS was flat and free cash flow fell 198.7%, each against the same quarter a year earlier.

4.70 0.09 −1.88%

Follow CSBR

Alert me

Market cap: $66.7M
P/E: 0.0×
Fwd P/E: −41.6×
Dividend yield: —
F-score: 3/9
Altman Z: −0.02
Beneish M: −1.80
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 56.18%

Capital & Financial Ratios $m

Market Cap 66.67

Revenue 60.66

Net Income (1.13)

Free Cash Flow (6.11)

Net Debt (4.36)

Current Ratio 1.03

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (41.60)

P/S ratio 1.08

P/B ratio 14.65

Past 5Y EPS Growth —

This Y EPS Growth (76.47%)

Next Y EPS Growth (16.67%)

Next Y revenue growth 9.82%

Next 5Y EPS Growth 15.00%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 2.03%

10-year low 10-year high

P/B against its own 10 years 22.47%

10-year low 10-year high

EV/Sales against its own 10 years 4.98%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	3	10	5	4
Receivables	10	11	13	14
Inventory	—	—	—	—
Other	—	—	—	—
	14	22	19	19

	2024	2025	2026	Q'26
Payables	6	4	7	6
ST’ Debt	—	—	—	—
Other	0	0	0	0
	22	24	20	19

Compound Annual Growth %

	10y	5y	3y
Sales	18.18%	7.68%	3.33%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	32.83%	(11.35%)	(4.26%)

Revenue $m

	Jul	Oct	Jan	Apr	Year
’26	15	—	—	—	—
’26	14	15	17	14	59
’25	14	13	17	12	57
’24	13	12	12	14	50
’23	14	14	13	13	54
’22	11	12	13	13	49
’21	10	10	11	11	41

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Jul	Oct	Jan	Apr	Year
’26	0	—	—	—	—
’26	1	(2)	(1)	(2)	(4)
’25	0	0	0	7	7
’24	(4)	1	(1)	(2)	(6)
’23	0	3	2	(1)	4
’22	0	1	4	1	6
’21	(1)	1	0	(2)	(2)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Jul	Oct	Jan	Apr	Year
’26	(1)	—	—	—	—
’26	1	(2)	(1)	(2)	(5)
’25	0	0	0	7	7
’24	(5)	1	(1)	(2)	(7)
’23	(1)	3	1	(1)	1
’22	(1)	1	4	0	4
’21	(1)	0	(1)	(3)	(5)

Fiscal quarters ending in the months shown.

EPS $

	Jul	Oct	Jan	Apr	Year
’26	(0.03)	—	—	—	—
’26	(0.03)	0.02	(0.02)	(0.05)	(0.08)
’25	0.09	0.05	0.31	(0.13)	0.33
’24	(0.19)	(0.15)	(0.19)	(0.01)	(0.54)
’23	(0.02)	0.00	(0.18)	(0.19)	(0.39)
’22	(0.01)	0.02	0.05	(0.03)	0.04
’21	0.01	0.00	0.05	(0.04)	0.02

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	2.19	3.05	4.98	4.02	7.75	3.75	3.95	3.60	5.59	4.59	Analyst estimates 2027–2029 Powerpack
	High	4.79	17.90	12.80	13.45	14.68	9.88	7.32	9.53	11.99	7.71
People
People	Employees	79	92	115	143	194	230	230	210	213	214
	Revenue/emp, $m	0.20	0.22	0.24	0.22	0.21	0.21	0.23	0.24	0.27	0.28
Income, $m
Income, $m	Revenue	15	20	27	32	41	49	54	50	57	59
	Gross margin, %	37.04	47.86	47.30	47.08	47.74	51.88	45.18	41.38	50.15	48.00
	EBT	(7)	(1)	0	(2)	0	1	(5)	(7)	5	(1)
	EBT margin, %	(44.55)	(7.13)	0.85	(6.11)	1.06	1.19	(9.78)	(14.57)	8.12	(1.56)
	Net income	(7)	(1)	0	(2)	0	1	(5)	(7)	5	(1)
	Depreciation	0	0	1	1	1	2	2	2	2	1
Per share, $
Per share, $	Revenue	1.44	1.84	2.39	2.71	3.12	3.72	3.98	3.70	4.17	4.30
	Earnings	(0.64)	(0.14)	0.01	(0.17)	0.03	0.04	(0.39)	(0.54)	0.34	(0.08)
	Cash flow	(0.27)	(0.11)	0.16	0.25	(0.13)	0.49	0.29	(0.45)	0.54	(0.32)
	Capex	(0.07)	(0.11)	(0.07)	(0.19)	(0.25)	(0.18)	(0.21)	(0.06)	(0.03)	(0.04)
	Free cash flow	(0.34)	(0.22)	0.09	0.06	(0.38)	0.31	0.08	(0.51)	0.51	(0.36)
	Book value	0.04	0.00	0.20	0.43	0.57	0.69	0.34	(0.14)	0.28	0.29
	Shares, m	11	11	11	12	13	13	14	14	14	14
Valuation, ×
Valuation, ×	P/E	0.00	0.00	908.00	0.00	414.29	190.75	0.00	0.00	20.43	0.00
	P/S	1.82	2.36	3.80	2.85	3.44	2.05	1.22	1.31	1.72	1.39
	P/B	70.25	15,900.31	46.01	17.93	18.98	11.07	14.20	0.00	25.89	20.27
	EV/Sales	1.61	2.32	3.69	2.59	3.32	1.87	1.04	1.26	1.55	1.31
	EV/FCF	(6.88)	(19.11)	97.11	121.43	(27.49)	22.31	50.72	(9.06)	12.57	(15.50)
Cash, $m
Cash, $m	Operating cash flow	(3)	(1)	2	3	(2)	6	4	(6)	7	(4)
	Capex	(1)	(1)	(1)	(2)	(3)	(2)	(3)	(1)	0	(1)
	Free cash flow	(4)	(2)	1	1	(5)	4	1	(7)	7	(5)
Balance, $m
Balance, $m	Working capital	(2)	(2)	0	1	1	2	(2)	(8)	(1)	(1)
	Total debt	0	0	0	3	9	8	7	—	—	—
	Net debt	(3)	(1)	(3)	(8)	(5)	(9)	(10)	(3)	(10)	(5)
	Shareholders’ equity	0	0	2	5	7	9	5	(2)	4	4
Returns, %
Returns, %	ROA	(99.85)	(18.35)	1.32	(13.07)	1.50	1.74	(15.31)	(24.08)	16.08	(3.96)
	ROIC	0.00	0.00	0.00	0.00	8.35	426.26	0.00	0.00	0.00	0.00
	ROE	(2,157.99)	(732.51)	11.42	(57.05)	5.78	6.63	(77.70)	(532.46)	503.05	(29.97)

Negative figures in brackets.

All 10 years →

Fiscal years to Apr 2026 · latest quarter Jul 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MAIA MAIA Biotechnology, Inc.	$69.2M	— (loss-making)	—	—	n/m	−63.23% (below 0%: shrinking)	—	0.00%	Compare
CSBR Champions Oncology, Inc.	$66.7M	— (loss-making)	— (loss-making)	+8.84% (above 0%: growing)	n/m	−198.74% (below 0%: shrinking)	50.54%	(2.69%)
OSTX OS Therapies Incorporated	$66.0M	— (loss-making)	—	—	n/m	−134.43% (below 0%: shrinking)	—	0.00%	Compare
HYFT MindWalk Holdings Corp.	$66.0M	— (loss-making)	— (loss-making)	+19.37% (above 0%: growing)	n/m	+9.79% (above 0%: growing)	58.58%	(159.86%)	Compare
NMAD Nomad Power Solutions, Inc.	$65.9M	— (loss-making)	—	—	n/m	−230.63% (below 0%: shrinking)	—	0.00%	Compare
XBIT XBiotech Inc.	$65.9M	— (loss-making)	— (loss-making)	−93.33% (below 0%: shrinking)	n/m	+25.25% (above 0%: growing)	0.00%	0.00%	Compare
SPRO Spero Therapeutics, Inc.	$65.8M	7.9×	4.2×	−95.61% (below 0%: shrinking)	n/m	+69.73% (above 0%: growing)	100.00%	0.00%	Compare
VRCA Verrica Pharmaceuticals Inc.	$64.9M	— (loss-making)	— (loss-making)	−53.85% (below 0%: shrinking)	n/m	+7.63% (above 0%: growing)	85.02%	(223.42%)	Compare
CING Cingulate Inc.	$63.8M	— (loss-making)	—	—	n/m	−24.28% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$65.9M	—	—	−73.59%	—	−8.32%	58.58%	0.00%

All 614 Biotechnology stocks →

Champions Oncology, Inc. (CSBR) key facts

Strength: Champions Oncology, Inc.’s revenue for fiscal 2026 (year ended April 2026) was $59.4 million, up 4.36% from fiscal 2025.
Champions Oncology, Inc. (CSBR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CSBR traded at $4.70, a market capitalization of $66.7 million.
Return on equity was −30.0% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −0.02 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.